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INTRODUCTION
The blood pressure (BP) is the force gen-
erated by the heart that drives circulation
of the blood. After Scipione Riva-Rocci
first introduced the sphygmomanometer at
the beginning of last century, for decades
arterial hypertension (hypertension) was
considered to be “essential” for securing
the perfusion of vital organs, as the brain,
heart, and kidney. The term “essentielle
hypertonie,” coined by the German clini-
cians, was indeed meant to underline the
fact that BP, alongside the heart beat, is the
essence of life, as there can be no life with-
out BP. This led to contend that the higher
the BP values, the better for vital organs
perfusion, a view testified by Paul Dudley
White’s, one of the top cardiologists of the
last century, statement: “Hypertension may
be an important compensatory mechanism,
which should not be tampered with, even
were it certain we could control it.”
It took the randomized clinical trials in
the eighties of the last century to disman-
tle this misconception, and finally prove
that lowering BP was beneficial, e.g., bet-
ter than placebo for lowering cardiovascu-
lar events (1–3). Hypertensiologists should
indeed be proud of the fact that anti-
hypertensive treatment has been the first
cardiovascular therapy whose efficacy has
been proven beyond doubts with random-
ized clinical trials and use of hard end
points. Several decades of epidemiologi-
cal and experimental research, along with
a number of further large-scale clinical tri-
als [reviewed in Ref. (4–6)], have now led
the widely accepted concept that hyperten-
sion is the “number one” cardiovascular
risk factor, not only because of its very high
prevalence but also for its tight relationship
with cerebro- and cardiovascular events.
In westernized countries around 40%
of the adult men and women have hyper-
tension, which puts them at an excess
risk of stroke, both hemorrhagic and
ischemic, acute coronary syndromes, heart
failure, and chronic kidney disease with
the ensuing need for renal replacement
therapy. Considering that worldwide about
13.5% of premature deaths were attrib-
uted to hypertension in 2001, the World
Health Organization defined hypertension




The increasing awareness of the detri-
mental effects of hypertension has been
paralleled by the development of an
overwhelming amount of knowledge on
cardiovascular pathophysiology. This has
had enormous fallout in the diagnos-
tic approach and treatment of many
other cardiovascular diseases. It has also
led to the development of effective
non-pharmacologic measures and phar-
macologic agents. Accordingly, current
guidelines recommend a number of life-
style changes to improve the control of BP
values, both in primary prevention and as a
valuable addition to pharmacologic treat-
ment. The latter has made terrific steps
since the Kempner fruits and rice diet, and
the first introduction of the ganglio-plegic
drugs in the sixties of the previous century.
Accordingly, more than 100 drugs, alone
or in predefined combinations, are now
available for the treatment of hyperten-
sion. Notwithstanding these progresses, far
too many hypertensive patients continue
to have BP far above the target values that
would be desirable based on their overall
cardiovascular risk profile. Current, esti-
mates of uncontrolled hypertension indi-
cate that up to 30–40% of the patients have
BP values above target. Hence, there are
several challenges that need to be addressed
in the near future (Table 1).
PROBLEM OF RESISTANT
HYPERTENSION
Considering that uncontrolled hyperten-
sion leads to excess target organ dam-
age and complications (9), the patients
with resistant hypertension (RH) are still
exposed to an excess risk of CV events
(10). Recognizing the importance of this
re-emerging problem the major scientific
societies, both in Europe and in North
America, have introduced the concept of
drug “resistant” or refractory hypertension
and developed definitions for this condi-
tion (Table 2). Albeit varying slightly across
societies, these definitions are useful in
drawing attention to this problem. They
also underline the fact that hypertension
is a heterogeneous condition whose patho-
physiological mechanisms still remain elu-
sive in many patients.
Hence, a major challenge for the coming
years entails developing more aggressive
research and novel therapeutic strategies
for RH, if we are not going to passively
accept a situation that takes still too many
lives every year worldwide.
CURRENT STRATEGIES TO FIGHT
HYPERTENSION
The general approach adopted thus far
by most international scientific societies
and national societies to address the issue
of improving the control of hypertension,
has been through the release of guide-
lines for the management of hyperten-
sion. For example, the European Society of
Cardiology (ESC) and the European Soci-
ety of Hypertension (ESH) have jointly
released guidelines repeatedly in the last
two decades (11–15) and more recently in
2013.
These guidelines are commendable in
that they provided useful practical infor-
mation on evaluation of biomarkers for
risk stratification, life-style measures, and

























































Rossi Mineralocorticoid receptor and right ventricle
Table 1 |The challenges of arterial hypertension.
•To develop more effective and widely applicable strategies for improving BP control worldwide
•To develop more aggressive strategies to diagnose and treat RH
•To integrate the top-down guidelines approach with diffuse postgraduate training programmes in
hypertension
•To increase the awareness and detection of secondary forms of hypertension
•To facilitate the detection, diagnosis, and treatment of primary aldosteronism
•To improve the detection and treatment of renovascular hypertension
•To investigate the feasibility of a genomic-based approach for individualizing the management of
arterial hypertension
Table 2 | Definitions of resistant hypertension according to major scientific societies.
Society/Year/Reference Definition
JNC 7 (2003) Failure to reach BP goal in patients who are adhering to full doses of an
appropriate 3-drug regimen that includes a diuretic
AHA Scientific
Statement 2008
“. . . blood pressure that remains above goal despite the concurrent use
of 3 antihypertensive agents of different classes. Ideally, one of the 3
agents should be a diuretic.” It includes patients whose blood pressure
is controlled but require 4 or more medications to do so
ESH/ESC Guidelines
2007
BP ≥140/90 mmHg despite treatment with at least 3 drugs (including a
diuretic) in adequate doses and after exclusion of spurious hypertension
such as isolated systolic hypertension and failure to use large cuffs on
large arms
BHS (2011) Someone whose BP is not controlled to <140/90 mmHg despite optimal
or best-tolerated doses of third line treatment
ESH/ESC Guidelines
2013 (15)
“. . . when a therapeutic . . . strategy that includes appropriate life-style
measures plus a diuretic and two other antihypertensive drugs belonging
to different classes at adequate doses (but not necessarily including a
mineralocorticoid receptor antagonist) fails to lower SBP and DBP values
to 140 and 90 mmHg, respectively”
JNC, Joint National Committee; AHA, American Heart Association; ESH, European Society of Hypertension;
ESC European Society of Cardiology; BHS, British Hypertension Society. Bold indicates the importance of
diuretics in the definition.
strategy of management, including use of
the most recent sympathetic renal dener-
vation and baroreceptor stimulation ther-
apy. However, in spite of their publication
in multiple journals, and notwithstanding
these progresses in treatment, the preva-
lence of uncontrolled hypertension did not
fall, but rather continued to rise. This is
clear-cut evidence that guidelines – based
approaches are by themselves not sufficient
to solve the problem of the poor BP control
at the population level. Looking at the lat-
est edition of the ESH/ESC guidelines some
reasons for this failure are readily evident.
The paper is made of 76 pages, 14 tables,
5 figures, and 735 references (15). This is
an overwhelming amount of information
that exceeds by far the amount evidence
that any busy general practitioner or
practicing clinicians dealing with a mul-
titude of patients crowding the waiting
rooms of their outpatient clinics can ever
possibly read. Recognizing this problem the
ESH has prepared a digest version of the
European guidelines, but the impact of this
“simplified” approach is still to be seen.
As common to other guidelines, the
method exploited in writing these guide-
lines was a“top-down” approach, e.g., from
level of evidence and class of recommenda-
tion, mainly produced by randomized clin-
ical trials, to practical advices, rather than a
problem-oriented “bottom-up” approach.
While understandable and obviously sci-
entifically sound, this top-down approach
contributed to building up the complexity
of the guidelines, and to produce their
resulting scant impact in clinical practice.
Hence, a major challenge facing the
hypertension community is to conceive
and develop novel strategies for continuous
medical education in the field of hyperten-
sion, having always in mind the final users,
e.g., the doctors and the patients.
Additionally, given the complexity of
the hypertension field, which requires a
multidisciplinary medical formation, with
notions spanning from cardiology, to
endocrinology, to internal medicine, to
nephrology to clinical pharmacology, at
least in Europe, there is an urgent need
for developing postgraduate training pro-
grams in hypertension. To the best of
my knowledge the only such programs is
the International PhD Program in Arterial
Hypertension and Vascular Biology, which
was developed at our University in 2001
in conjunction with the Medical Acad-
emy of Gdansk and with Charitè Univer-
sity in Berlin and is to be extended to the
University of Maastricht next year.
UNDER DIAGNOSIS AND UNDER
TREATMENT OF SECONDARY
HYPERTENSION
Undiagnosed forms of secondary hyper-
tension likely contribute substantively to
the on-going epidemics of uncontrolled
hypertension. Currently, at referral cen-
ters for hypertension, up to 25% of the
patients are found to be affected by sec-
ondary forms of hypertension, a figure 5-
to 10-fold higher than those reported in the
major textbooks. The latter reported data
mainly based on dated epidemiologic stud-
ies that mostly made use of obsolete diag-
nostic strategies. This apparent increase
in prevalence of secondary hypertension
means that if a proper diagnostic workup
were systematically exploited, an underly-
ing cause of hypertension could be identi-
fied in about one patient every four. Hence,
a substantial proportion of the patients
now mislabeled as “essential hypertension”
can thus be either long-term cured or, at
least, their BP values can be brought under
control, as recently shown to be the case for
primary aldosteronism (16).
In spite of the high rate of secondary
hypertension, in the most recent ESC/ESH
guidelines only a quarter page was devoted
to the screening and diagnostic workup
of these forms (15), which left practicing

























































Rossi Mineralocorticoid receptor and right ventricle
physicians with the perception that this is a
“niche” problem, while it is altogether evi-
dent that it is not. Of little help in this
regard was the release of specific guide-
lines for some endocrine forms of sec-
ondary hypertension, including primary
aldosteronism (17) and pheochromocy-
toma (18). These guidelines were prepared
by “specialists for specialists.” Therefore,
they are perceived to be too complex to be
effectively implemented into clinical prac-
tice. Accordingly, far too many potentially
curable patients are left with a questionable
diagnosis of primary (essential) hyperten-
sion simply because they were not properly
investigated beforehand.
THE PROBLEM OF PRIMARY
ALDOSTERONISM
There is no doubt that primary aldostero-
nism is the most common endocrine, and
probably also the most under diagnosed
and under treated, cause of hypertension.
As a result of this, many patients, who could
be long-term cured (16), are exposed to
antihypertensive treatment for their entire
lifetime. At the same time, they remain
exposed to an excess risk of CV events.
A number of reasons can account for this
ominous situation. The still diffuse, albeit
wrong, perception that primary aldostero-
nismisexceptionally rare is thefirstof them.
The second entails the fact that, as already
mentioned, the diagnostic workup is too
complex (17). The development of simpli-
fied diagnostic algorithms based on novel,
omics-derived biomarkers is therefore, a
major challenge for the hypertension com-
munity for the years to come. These algo-
rithms could then be used to screen these
patients leading to a more targeted treat-
ment with ensuing improved BP control.
THE PROBLEM OF ATHEROSCLEROTIC
RENOVASCULAR HYPERTENSION
Atherosclerotic renal artery stenoses
(ARAS) are increasingly found due to
aging of the population. They account
for about 90% of all renal artery lesions
(19) and, through cholesterol emboli, they
can lead to cortical infarcts, ischemic
nephropathy, and eventually chronic
renal failure. Moreover, through activa-
tion of the renin–angiotensin–aldosterone
system (RAAS) they have other nefarious
effects, including inflammation, oxidative
stress, endothelial dysfunction, hyper-
tension, thus accelerating widespread
cardiovascular disease (20).
Although stenosis is generally held
to attain hemodynamic significance only
when the luminal narrowing is at least 70%,
as compared to the nearby unaffected vessel
or, if between 50 and 70%, when the trans-
stenotic peak or mean pressure gradient
is >20 or >10 mmHg, respectively (21),
these threshold values are to be regarded
cautiously as discussed elsewhere (22).
Until 1978, when Grüntzig introduced
percutaneous transluminal renal angio-
plasty (PTRA) (23), patients with ARAS
were treated medically or surgically. Obser-
vational, retrospective, and controlled trials
thereafter suggested that PTRA could be
beneficial over medical treatment for pre-
serving renal function and improving BP
control if followed by stenting [reviewed
in Ref. (22)]. However, PTRA plus stent-
ing (PTRAS) could not unequivocally be
shown to overcome medical therapy in
the few available randomized clinical tri-
als. These trials, however, had limitations
in study design, inclusion and exclusion
criteria, and treatment options that led
to seriously challenge their results and
conclusions (24–26).
A recent meta-analysis of seven studies
comprising a total of 2155 patients, includ-
ing the recently reported CORAL Study,
showed that compared to baseline, diastolic
BP fell more at follow-up in patients in the
endovascular than in the medical treatment
arm (P = 0.002) (22). Moreover, patients
with ARAS receiving endovascular treat-
ment required less anti-antihypertensive
drugs at follow-up than those medically
treated. Hence, the lower diastolic BP was
achieved despite a greater reduction in the
mean number of antihypertensive drugs
(necessary to control BP (P < 0.001) (22).
Identical conclusions were reached by at
least three meta-analyses: the first on 527
patients recruited in five prospective mul-
ticentre FDA-approved trials (27), the sec-
ond, a Cochrane meta-analysis, for both
diastolic BP and lowered antihypertensive
therapy (28), and the third for lowered
antihypertensive therapy (29).
Conclusive evidence that PTRAS low-
ers incident cardiovascular and renal events
more than medical therapy in patients
with ARAS remains, however, to be pro-
vided, likely because all these studies were
too small in size and too short in dura-
tion to achieve this result. Accordingly,
the optimal treatment of ARAS patients
remains a highly controversial issue. Cur-
rently, this translates in ample variation
in clinical practice, even though available
guidelines on treatment of ARAS identified
some compelling indications to revascular-
ization. These recommendations are based
on class I, level of evidence B (Table 3) (30).
Therefore, another major challenge is
to plan well-designed clinical research to
improve clinical care of the increasing num-
ber of elderly patients with atheroscle-
rotic renal artery stenosis and hypertension.
The Medical and Endovascular Treatment
of Atherosclerotic Renal Artery Steno-
sis (METRAS) now on-going (METRAS
study)1 (31) can be an example of these.
GENDER-RELATED DIFFERENCES IN BP
There are clear-cut gender-specific differ-
ences that contribute to the well-known
dimorphism in CV risk between genders:
fertile women have lower BP values than
age-matched men; the opposite is true
after menopause. Notwithstanding this,
the mechanisms underlying this BP gen-
der dimorphism are just starting to be
unraveled. For example, investigating the
gender-related regulation of aldosterone
production Caroccia et al recently found
a major role for estradiol. The estrogen
tonically inhibits aldosterone production
by acting through beta-receptor, as when
this effect is removed by pharmacological
blockade or molecular knocking down of
this nuclear receptor, the hormone exerts a
potent stimulatory role on aldosterone pro-
ductionactingviatheGEPR-1receptor(32).
Establishing whether such mechanisms is
important for determining the changes in
BP values in women with aging, during the
menstrual cycle, or during long-term treat-
ment with estrogen-receptor modulators,
which are being prescribed to a multitude
of women with estrogen-receptor positive
breastcancer,isakeyquestiontobeaddressed
with specific research in the future decade.
1http://clinicaltrials.gov/ct2/show/NCT01208714
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Table 3 | Questions that need to be answered in future trials in hypertension.
• Does the lower BP the better the outcome apply to all conditions and organs?
• Are there long-term benefits, e.g., beyond the duration of the RCT?
• Are there BP-independent protective properties that differ among different classes of
antihypertensive drugs?
• Is there a protective effect of lowering BP in acute stroke?
• Does antihypertensive treatment prevent cognitive function decay/dementia?
• Is there a beneficial effect of early treatment in delaying target organ damage/reduce residual risk?
• Does BP variability represent a target for treatment beyond absolute BP values?
• Are there beneficial effects in mild hypertensives, who are at low-intermediate risk?
•What are the real beneficial effects of life-style changes in reducing long-term risk?
•What is the clinical efficacy of the gene-based prescribing strategy?
• Does the increment in efficacy or safety overcome the cost of genetic testing?
•Will genetic stratification be useful in clinical trials to evaluate new drugs?
•Will genetic information be valuable for the design of new agents that are likely to produce less
adverse effects in genetically susceptible patients?
LIGHTS AND SHADOWS OF GENOMICS
OF HYPERTENSION
In the last two decades, impressive efforts
and resources have been devoted to the
search for the genes causing hypertension.
Advancements have been accomplished
for some monogenic forms, like Familial
Hyperaldosteronism (FH)-1 (GRA), Lid-
dle syndrome, Gordon syndrome, and
more recently FH-3 (33–35). Almost
invariably the rewarding strategy has
been to start from phenotypically well-
characterized pedigrees, mostly involving
cases of endocrine hypertension, use link-
age analysis to pinpoint the underlying
genes and mutations. Results of large-scale
association studies have not, however, been
equally impressive and rewarding even with
use of the more sophisticate and expen-
sive genome-wide scanning studies. Even
when association of BP with genetic vari-
ants were identified, the relative risk of
hypertension in the individual carrying the
variants was tiny. Consequently, the impact
of these studies on clinical practice has been
negligible.
A major challenge for the future is there-
fore to improve the stratification of the
hypertensive patients not only for gender,
age, and/or BP values but also for traits that




Pharmacogenomics is attracting increas-
ing attention in scientific circles and in
the popular press, mainly because of the
promise of personalized Medicine. Short
of being able to cure or to prevent hyper-
tension in the majority of the cases,
genomics research might eventually ful-
fill every hypertensiologist’s dream, which
is to move from the current “trial-and-
error” drug treatment strategy to offering
patients a precisely targeted drug at a pre-
cisely calibrated dose – and to do so without
wreaking adverse effects.
While the vision of uncovering new tar-
gets for pharmacologic intervention and
of creating novel agents for individualized
treatment glimmers tantalizingly distantly
on the horizon, much closer to applica-
tion might be the use of information about
how genetic variations affect the efficacy
of drugs to guide prescribing decisions for
agents currently on the market.
There are sound reasons to predict that
pharmacogenomics will eventually succeed
in fulfilling this is promise. Technological
advances that enable to identify millions
of DNA sequence variations swiftly and
inexpensively, and to correlate them with
phenotypic characteristics, are occurring
with a restless rhythm (36). Indeed, it
is conceivable that someday soon DNA
sequencing will be a routine part of the
workup for hypertensive patients, at the
very least to identify a patient’s sensitivity
to drugs that are likely to produce adverse
effects.
The National Institutes of Health con-
sortium on pharmacogenetics research
network (PGRN) is collecting information
on how genetic variation contributes to dif-
ferences in drug response among patients
and data about specific proteins, genes,
and pathways is being integrated into the
Pharmacogenetics and Pharmacogenomics
Knowledge Base (37). Hence, we might
not be a long way from the day when a
patient presents a DNA “chip,” a key-chain
tag bearing his electronic health record, to
a physician and gets a dose of personalized
treatment of hypertension.
However, a good deal of research still
needs to be performed in clinical trails
to address multiple questions (Table 3).
Among such questions a major place
regards the clinical trials to evaluate the
clinical efficacy of the gene-based prescrib-
ing strategy, and to determine whether
the increment in efficacy or safety war-
rants the cost of genetic testing. Moreover,
genetic stratification in clinical trials will
be needed to evaluate new drugs – and
indeed, genetic information will be invalu-
able for the design of new agents to serve as
alternatives to existing drugs that are likely
to produce adverse effects in genetically
susceptible patients.
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